businesses
Project of 1 832 909 $ over 2 years
- Supported by CQDM through:
Ministère de l’Économie, de l’Innovation et de l’Énergie du Québec (MEIE) - By co-funding partners:
9Bio Therapeutics, Vega BioImaging - And by project partner:
IVADO
Project summary
Despite significant advances, many forms of cancer remain difficult to treat and are associated with poor prognoses, highlighting the urgent need for new therapeutic solutions. Leveraging its proprietary platform that combines structural biology, AI, and custom protein design algorithms, 9Bio Therapeutics is developing an antibody-based targeted therapy for multiple cancer types. Meanwhile, Vega BioImaging incorporates the antibodies created by 9Bio into its proprietary protein-labelling kit to determine, via a biopsy, the patient’s eligibility for 9Bio’s targeted therapy. Unlike conventional techniques, Vega’s integrated nanotechnology, high-precision optical system and AI algorithm enable quantitative, multiplexed detection of biomarkers, offering a faster, more precise tool for patient stratification in both clinical trials and healthcare settings.
